Abstract 5117
Background
Monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio are considered prognostic tools of overall survival (OS) in several hematologic and solid tumors. All these elements have been implicated as biomarkers of tumor microenvironment and immune homeostasis. Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy (5%–7% of malignant lymphoma) but could be very aggressive. Mantle Cell Lymphoma International Prognostic Index (MIPI) is the only validated prognostic tool for these patients. The aim of this study assessed the prognostic significance of monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio as prognostic biomarkers for MCL.
Methods
An observational retrospective study was conducted and included a total all the patients diagnosed with MCL between 2008-2018 in our hematologic center. The ratios were calculated, and statistical analysis were assessed using Kaplan-Meier method, log-rank test and Cox regression. All the analyses were performed using SPSS.
Results
A total of 52 patients were included, 75% were male, with the median age at diagnosis being 67 years-old (max 94, min 36 years old). 77% of the patients had an ECOG PS 0-1, 67% had a high risk MIPI and 73% were a stage IV disease at diagnosis. Kaplan-Meier analysis showed that MIPI score significantly predicts the OS of the patients, with the higher scores being associated with inferior OS (p = 0,02). The same did not happen with the monocyte-lymphocyte ratio (p = 0,5), neutrophil-lymphocyte ratio (p = 0,4) and platelet-lymphocyte ratio (p = 0,3). The same results were showed in cox regression, MIPI score remained the only score associated with OS (HR, 0,35; 95% CI 0,132-0,962).
Conclusions
In conclusion, this study fails to identify monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic tools and support MIPI as predictor of the survival outcome in MCL patients and its ability to identify high-risk patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract